This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Catalent Pharma Solutions, Inc.
Catalent Pharma Solutions, Inc., a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products, is headquartered in the United States. Founded in 2007, Catalent has rapidly expanded its operations across North America, Europe, and Asia, establishing a strong presence in the pharmaceutical and biotechnology industries. The company is renowned for its innovative core services, including drug formulation, clinical supply services, and commercial manufacturing, which are designed to enhance product efficacy and patient compliance. Catalent's commitment to quality and efficiency has positioned it as a trusted partner for many of the world's top pharmaceutical companies. With a focus on continuous improvement and cutting-edge technology, Catalent Pharma Solutions continues to achieve significant milestones, solidifying its status as a leader in the life sciences sector.
DitchCarbon Score
How does Catalent Pharma Solutions, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Catalent Pharma Solutions, Inc.'s score of 48 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Catalent Pharma Solutions, Inc., headquartered in the United States, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas emissions. Although specific emissions data for the most recent year is not available, the company has established clear targets through the Science Based Targets initiative (SBTi). Catalent commits to reducing its absolute Scope 1 and Scope 2 greenhouse gas emissions by 42% by FY2030, using FY2022 as the baseline year. Additionally, the company aims to cut its absolute Scope 3 emissions—specifically from fuel- and energy-related activities and employee commuting—by 25% within the same timeframe. Furthermore, Catalent plans for 70% of its suppliers, measured by emissions, to have science-based targets by FY2028, covering areas such as purchased goods and services, capital goods, and upstream transportation and distribution. These targets reflect Catalent's commitment to align with the necessary reductions to limit global warming to 1.5°C, demonstrating a proactive approach to climate action within the pharmaceutical and biotechnology sector. The data and commitments are cascaded from Catalent, Inc., which operates as a current subsidiary of Catalent Pharma Solutions, Inc.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 61,000,000 | - | - | 00,000,000 | 00,000,000 |
| Scope 2 | 144,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Catalent Pharma Solutions, Inc. is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
